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Purpose: In Italy, where the adoption of opioid analgesics in pain management has been his-
torically poor, an increase in opioids consumption occurred between 2000 and 2015. The aim 
of this study is to assess, through specific time series analyses for trend changes, the impact of 
different intervening factors – such as the availability of new drugs, the observance of clinical 
guidelines, changes in prescription regulations, and in reimbursement policies – on opioids sales 
to community pharmacies in Italy, focusing on the time period 2000–2010.
Materials and methods: Five opioids were considered: codeine, tramadol, buprenorphine, 
morphine, and fentanyl. The analysis is based on sales data collected at wholesale distributors. 
For each one of the five drugs, time series of the number of Defined Daily Doses per thousand 
inhabitants per day in the period 2000–2010 were analyzed, and an estimation of breakpoints 
was performed using segmented linear regression.
Results: Drug sales underwent a sharp increase in 2000–2010, although on different scales. 
Segmented regression analysis highlighted different potential breakpoints, corresponding to 
either a significant change in value and/or in slope. Sales of the five opioids were affected by 
at least one relevant event, often due to a synergy of regulatory, marketing, and technological 
factors. The effect of reimbursement changes has proved important.
Conclusion: Between 2000 and 2010, regulatory, technological, and reimbursement changes 
significantly influenced opioid sales to community pharmacies in Italy. The sales of relatively new 
drug products seem to be less influenced by changes in reimbursement and regulatory policies 
than that of more established products, suggesting that physicians are more comfortable with 
“old” drugs, since their clinical use is supported by established clinical guidelines and protocols.
Keywords: opioids sales, community pharmacy, reimbursement policy, legislation changes, 
breakpoint estimation
Introduction
In the last decades, the management of pain caused by chronic and progressive incur-
able illnesses has become a central focus of healthcare systems in assuring an accept-
able quality of life to patients.1 Although the World Health Organization (WHO) has 
introduced specific guidance for pain management,2 the adoption of opioids analgesics 
in pain management has remained poor in some western countries.3 Some authors and 
the WHO ascribed the under-treatment of pain with opioids to stringent legislation 
and control,3,4 while other authors showed that factors such as the marketing of new 
drugs, changes in reimbursement policies, cultural changes, and increased patients’ 
awareness also had a significant impact.5–7
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On the other hand, the abuse potential of opioids cannot 
be underestimated. In some countries, an excessive increase 
in opioid prescription in the last 15 years has led to an opioid 
epidemic, which, although relatively absent in Europe, has 
gained the proportion of a public health crisis in the United 
States. Therefore, efforts are directed toward gaining a deeper 
understanding of pain and toward the development of novel, 
nonaddictive analgesics.8,9
In a previous report, opioids sales from 2000 to 2010 were 
analyzed separately by distribution setting, to highlight the 
differences between community pharmacies and hospitals.10 
The study showed an overall increase in opioids sales, with 
a much higher relative growth in community pharmacies. 
However, the reasons for that increase were not rigorously 
analyzed.
The aim of this study is to assess, through specific time 
series analyses for trend changes, the impact of legislation, 
reimbursement by the Italian National Health System (NHS), 
and availability of new drugs or new dosage forms on the 
sales of opioids for pain management to Italian community 
pharmacies between 2000 and 2010. Italy is an ideal setting 
for such an analysis, since a clear-cut steady increase in 
opioid consumption occurred in that period.10 After 2011, 
the increase seemed to level off.11 The statistical analysis 
focused on the period 2000–2010, when the most important 
reimbursement and legislative changes took place.
Materials and methods
Original data were quarterly number of packs sold to com-
munity pharmacies in the period 2000–2010 (supplied by 
IMS Health S.r.l, Italy). Only five opioids used in pain 
management were considered: codeine, tramadol, buprenor-
phine, morphine, and fentanyl (Table 1). The data obtained 
from sales of oxycodone and hydromorphone – introduced 
in Italy, respectively, in 2005 and 2008 – were not analyzed 
due to the limited sample size in the considered time series. 
Methadone was also excluded from the analysis, since it 
is mainly prescribed to patients with opioid addiction. For 
each specific commercial product, the total amount in mil-
ligrams was calculated by multiplying the number of packs 
sold by the number of units per pack by the amount of drug 
(mg) per unit.
The dosage forms included in the analysis were: con-
ventional oral dosage forms for codeine and tramadol (drug 
products in association with paracetamol), conventional and 
modified release oral dosage forms, and solution for injection 
for tramadol and morphine. Immediate release oral dosage 
forms and transdermal patches for fentanyl and buprenor-
phine; transmucosal oral dosage forms for fentanyl and 
solution for injection for buprenorphine. Further details are 
listed in the previous report.10 Review and approval was not 
required for this research by an institutional review board or 
ethics committee, because it does not involve human subjects 
and only involves the use of de-identified aggregated data.
Relevant events
In this section, the most relevant events that may influence 
opioids sales are highlighted. In particular, changes in the 
regulatory framework of drug prescription for pain manage-
ment or in reimbursement policies and the availability of new 
active substances or dosage forms (Table 1). Noteworthy, 
some of the events are very closely spaced, and attributing 
a change in sales to one unique cause proved difficult in 
some cases.
Table 1 Different steps in the italian opioids market and prescription regulation
Line Date Description
R1 first Q 2001 easier prescription for all opioids for patients suffering from severe 
pain due to neoplastic or degenerative disease
M/T1 second Q 2001 introduction of morphine oral solution
M/T2 second Q 2003 introduction of buprenorphine transdermal patch
M/T3 fourth Q 2004 introduction of oxycodone
Reim1 first Q 2005 Reimbursement by the it-nhs of most opioids
M/T4 first Q 2005 introduction of oral transmucosal fentanyl
M/T5 fourth Q 2005 introduction of generic of transdermal fentanyl
R1a third Q 2006 easier prescription for tramadol
R2 second Q 2007 easier prescription for opioids extended to all patients
M/T6 second Q2007 switch from reservoir to matrix technology for transdermal fentanyl
M/T7 third Q 2007 introduction of hydromorphone
R3 first Q 2008 Further simplification for low dose oxycodone prescription
R4 third Q 2009 Revocation of the special prescription pad for all opioids (except for 
parenteral morphine and oral buprenorphine)
Note: i=1, 2, etc.
Abbreviations: R(i), i-th regulatory break; M/T(i), i-th market/technology break; Reim(i), i-th reimbursement break (a special case of regulatory break); Q, quarter.
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Factors affecting opioids consumption
Relevant regulatory interventions on opioids 
prescribing
Changes in the regulatory framework (marked with R) 
are summarized in Table 1 and briefly described in this 
paragraph.
Law n. 12 of February 8, 2001. In effect: March 6, 2001 
(R1). The law introduces a simplified prescription pad (called 
RMR) for a number of active substances (included in Annex 
III bis), destined to patients suffering from severe pain due 
to a neoplastic or degenerative disease. The RMR prescrip-
tion pad is in effect since June 12, 2001 (Decree of May 
24, 2001). The original Annex III bis of 2001 contained 10 
drugs: buprenorphine, codeine, dihydrocodeine, fentanyl, 
hydrocodone, hydromorphone, methadone, morphine, oxy-
codone, oxymorphone.
Decree of the Ministry of Health of June 19, 2006. In 
effect: July 11, 2006. Only relevant to tramadol (R1a). Tra-
madol (not included in Annex III bis, and prescribable with a 
standard non-repeat prescription, so called RNR), is excluded 
from the list of drugs of abuse. No changes to prescription 
regulations for tramadol are made.
Decree of the Ministry of Health of April 18, 2007. In 
effect: April 29, 2007 (R2). The active substances listed 
in Annex III bis can be prescribed to all patients, not only 
patients suffering from severe pain due to neoplastic or 
degenerative disease.
Decree of December 21, 2007. In effect: February 13, 
2008. Only relevant to Oxycodone (R3). The prescription 
requirements for oral drug products containing low dosages 
of oxycodone are simplified. In particular, doses lower than 
10 mg can be prescribed using a standard RNR, instead of 
the RMR prescription needed for the other Annex III bis 
drugs.
Ministerial decree (Ordinanza) of June 16, 2009. In 
effect: June 20, 2009 (R4). Except for parenteral morphine, 
the medicinal products containing active substances listed 
in Annex III bis can be prescribed using the standard RNR 
instead of RMR prescription. Prescription of parenteral 
morphine is addressed in the subsequent Law n. 38 of March 
15, 2010.
Law n. 38 of March 15, 2010. In effect: April 3, 2010. 
Only relevant to parenteral morphine. All the medicinal prod-
ucts used in pain management and reimbursed by the National 
Health System can be prescribed using standard RNR.
changes in reimbursement policies
Through the years, reimbursement policies for opioid 
analgesics distributed through community pharmacies 
have changed. For some medicinal products, reimburse-
ment by the NHS started before the period considered in 
the analysis. For medicinal products containing tramadol, 
codeine, buprenorphine, and oxycodone, on the other hand, 
reimbursement started after January 1, 2005.12 Initially, 
reimbursement for tramadol and codeine was restricted to the 
treatment of patients suffering from pain due to a neoplastic 
or degenerative disease. Such restrictions were eliminated 
in 2005 for codeine13 and October 2009 for tramadol.14 The 
only relevant change in reimbursement policy is marked with 
Reim1 in Table 1.
introduction of new active substances or dosage 
forms on the market
The availability of new drugs or new dosage forms is marked 
with M/T in Table 1. Since the Marketing Authorization does 
not generally coincide with the availability on the market of 
a new medicinal product, the timeline in Table 1 refers to the 
emergence of sales figures in the analyzed data.
statistical analyses
Opioid amounts in milligrams are standardized using the 
Defined Daily Dose (DDD) methodology recommended by 
the World Health Organization (WHO) for drug consump-
tion studies. The official DDD values are established by the 
WHO Collaborating Center for Drug Statistics Methodol-
ogy: transdermal and parenteral buprenorphine, 1.2 mg; 
oral codeine, 90 mg; sublingual/buccal fentanyl, 0.6 mg; 
transdermal fentanyl, 1.2 mg; parenteral morphine, 30 mg; 
oral morphine, 100 mg; oral tramadol, 300 mg.15
For each one of the five drugs considered, the time series 
of the number of DDDs per thousand inhabitants per day 
were analyzed. Data on resident population for each year in 
the period 2000–2010 was obtained from official reports of 
the Italian National Institute of Statistics.16
After a graphical descriptive examination of the whole-
sales time series for the five opioids considered, the potential 
impact of the interventions in the regulatory and technologi-
cal field was tested through the estimation of breakpoints, 
ie, points in which data show deviations from stability in the 
background trend.
For each one of the five opioids considered, the estimation 
of breakpoints was performed using segmented linear regres-
sion, in which a maximum four a priori unknown breakpoints 
are allowed.17 With four breakpoints, the considered interval 
of time is divided into a maximum of five segments in which 
the regression coefficients are kept constant, and a different 
model is estimated in each of these intervals. The model 
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can be written through the following regression equation: 
y
t
=α
j
+β
j
*t+ε
t
, where j=(1,…,5), t=T
j−1+1
,…,T
j
, ε
t
~N(0, σ2).
Breakpoints estimates are obtained by minimizing the 
residual sum of squares of the regression equation; the 95% 
CI for each breakpoint estimated is also reported.
Data analyses are performed using Stata 13.0 (StataCorp 
LLC, College Station, TX, 2013)18 and R software (R Core 
Team, Vienna, Austria, 2013),19 in particular the library 
Strucchange.20
Results
Sales data for the five selected opioids are shown in Figure 
1. Both Step II and Step III drugs sales have undergone a 
sharp increase, although on different scales. The greatest 
increase is observed for fentanyl, whereas morphine shows 
the only negative trend.
Segmented regression analysis highlighted different 
potential breakpoints, corresponding to either a significant 
change in value and/or in slope. The segmented regression 
lines and the estimated breakpoints are shown in Figure 2. 
An overview of all the potential breakpoints is shown in 
Figure 3.
codeine
Three breakpoints are estimated for the time series of codeine 
(Figure 2). The second breakpoint is at Reim1 (Table 1). The 
observed decrease in value and increase in slope may be 
explained with the availability of oxycodone in the fourth 
Quarter of 2004 and the change in reimbursement policies 
in the first Quarter of 2005. The last breakpoint in the third 
Quarter of 2007 may be related to the easier prescription 
being extended to all patients.
Tramadol
A sharp increase (in value and slope) in the first Quarter of 
2005 seems to be related to the change in reimbursement 
policies. Two breakpoints are located after the first Quarter 
of 2007, where the slope decreases (R2 and R4). Both results 
may be due to the fact that tramadol did not benefit from those 
normative interventions, despite the easier prescription (R1a) 
starting in the third Quarter of 2006 (Figure 2).
Morphine
Morphine shows the only decreasing trend. A first decrease 
in the second Quarter of 2001, despite the easier prescription 
(R1) and the availability of oral solution (M/T1), and a second 
decrease in the fourth Quarter of 2004, in conjunction with 
the introduction of Oxycodone and transmucosal Fentanyl. 
The decrease may be ascribed to a missed reimbursement 
policy change in the first Quarter of 2005 (Figure 2).
Fentanyl
Fentanyl shows a decrease in slope in the first Quarter of 
2004, following the availability of buprenorphine transdermal 
patches (second Quarter 2003). The decline continues in the 
third Quarter of 2007, followed by an upward trend in slope, 
after the Decree of second Quarter 2009 (R4) (Figure 2).
Buprenorphine
Buprenorphine sales start in a downward trend that shows a 
first reversal upon the introduction of transdermal patches 
in the second Quarter of 2003. The promising results of the 
transdermal dosage form are hidden by the breakpoint occur-
ring with the change in reimbursement policies in the first 
Quarter of 2005 (Figure 2).
Discussion
Opioids sales in community pharmacies in Italy showed a 
positive trend in the period 2000–2010 (Figure 1), in agree-
ment with the trend observed in the European Union.7,21 
Although regulatory interventions impacted sales in both 
community pharmacies and hospitals,10 the sales in commu-
nity pharmacies are particularly interesting for determining 
the role of a less stringent regulation for opioids prescription. 
Indeed, unlike hospitals where sales of different opioids are 
more affected by payer’s policies and, probably, by guidelines, 
in community pharmacies, sales are more directly related 
2000 q1
0
0.
5
1
1.
5
2
2002 q1 2004 q1 2006 q1
Date
Codeine Tramadol
MorphineFentanyl
Buprenorphine
2008 q1 2010 q1
Figure 1 sales of WhO step ii and step iii opioids to community pharmacies 
between 2000 and 2010. Data in DDDs/day/1000 inhabitants.
Abbreviations: WHO, World Health Organization; DDD, defined daily dose; q, 
quarter.
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to the influence of regulation and marketing on prescribing 
physicians.
The analysis shows that sales of all the five opioids were 
affected by at least one relevant non-clinical factor between 
2000 and 2010 (Figure 3). Furthermore, as previously reported 
by Mercadante,5 the overall positive trend varies from drug to 
drug, suggesting that the considered factors affect the prescrip-
tion of different opioids to different degrees.
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Figure 2 segmented regression results for opioids sales to community pharmacies between 2000 and 2010. Data in DDDs/day/1000 inhabitants (note the different scales). 
Dashed lines indicate estimated breakpoints.
Abbreviations: DDD, defined daily dose; inhab, inhabitants; q, quarter.
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The effect of technological 
innovation
The influence of technological innovation on opioid con-
sumption may be better analyzed comparing the trends of 
step III opioids. Fentanyl and morphine sales (Figure 2) 
were comparable to that of other European Countries,22 and 
almost superimposable to data observed in Nordic Countries7 
and Israel.23 The sales of fentanyl increased from 0.011 to 
0.468 DDDs/day/1000 inhabitants between 2000 and 2010, 
whereas morphine sales decreased from 0.113 to 0.084 
DDDs/day/1000 inhabitants in the same period (Figure 2).
The positive trend of fentanyl sales may be due to a 
synergy of regulatory, marketing, and technological factors. 
As reported by Chinellato et al,24 the regulatory interven-
tions induced a higher growth rate in fentanyl rather than in 
oral morphine prescriptions, even though no difference in 
prescribing laws and reimbursement policies were in place 
(Figure 2). Indeed, oral morphine solution and fentanyl 
transdermal patches were added to the list of reimbursable 
drugs by the Italian NHS almost simultaneously.24 Therefore, 
the different response to regulation changes may be due to 
the technological differences between the two dosage forms: 
transdermal patches are considered non-invasive systemic 
delivery systems, easy to stop and more manageable in 
comparison to an oral syrup or tablet. Furthermore, their use 
is correlated to a lower risk of misuse and to higher patient 
compliance.25 Such advantages seem to affect physicians’ 
willingness to prescribe transdermal fentanyl instead of oral 
morphine, despite recommendations in international guide-
lines to prescribe transdermal fentanyl only as an alternative 
to oral morphine.26,27
It is noteworthy to observe that the availability of a par-
ticular pharmaceutical form is more relevant to opioids sales 
by community pharmacies than by hospitals, where patients’ 
compliance is less critical in assuring treatment persistence 
of patients.10 Physicians’ concerns about the risk of misuse 
seems to be another critical issue in understanding prescrip-
tion choices. Indeed, fentanyl showed increased sales after 
the technological switch from reservoir to matrix formulation 
in 2007 (M/T6; Table 1). This change was required, since 
pharmacovigilance alerts had highlighted the risk of abuse 
related to oral absorption of the fentanyl-containing gel 
present in the reservoir transdermal patches.28 The matrix 
transdermal patch minimizes the risk of recreational abuse 
(the less the ease of drug extraction from dosage form, the 
less the risk of abuse) and brings additional advantages, 
such as the possibility to cut the patch, allowing for a more 
manageable dosage.
The introduction of therapeutic alternatives to fentanyl, 
namely buprenorphine transdermal patches (M/T2; Table 1) 
and oxycodone (M/T3; Table 1), slightly affected sales in the 
first part of 2004 (Figure 2). As in the case of transdermal 
fentanyl, buprenorphine showed an increase in sales when 
transdermal patches were made available in the second 
Quarter of 2003 (M/T2; Table 1). However, the results of 
transdermal buprenorphine are far from that of transdermal 
fentanyl in terms of sales (Figure 1), suggesting that greater 
caution is used by physicians in prescribing transdermal 
buprenorphine. Physicians’ preference for transdermal fen-
tanyl was confirmed in 2005, when the increase in sales of 
transdermal buprenorphine, by then reimbursed by the NHS 
(Reim1; Table 1), was stopped by the availability of generic 
transdermal fentanyl on the market (M/T5; Table 1).
The effect of reimbursement changes
The effect of reimbursement changes on opioid sales may 
be better clarified by comparing the data of Step II opioids 
(codeine and tramadol). Sales were positively influenced by 
regulatory implementations (Figure 2), but differences were 
Codeine
20
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20
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 q1
20
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 q1
20
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 q1
20
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 q1
20
10
 q1
Tramadol
Morphine
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Buprenorphine
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Figure 3 Overall synthesis of breakpoints estimated using segmented linear 
regression. The segments indicate the 95% cis of the break point estimates, for 
each drug considered.
Abbreviation: CIs, confidence intervals; q, quarter.
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observed depending on reimbursement policies. In the last 
part of 2004, both drugs reported a growth in sales, when 
NHS reimbursement for patients suffering for severe pain 
due to neoplastic or degenerative disease was introduced. 
For codeine, there was a temporary trend inversion at M/
T3 (Table 1). In the same period, tramadol sales showed an 
increase of comparable magnitude. Nevertheless, codeine 
consumption continued to increase after that, as the reim-
bursement restriction was removed (Reim1; Table 1) and 
prescription to all patients was made possible in 2007 (R2; 
Table 1). Tramadol prescriptions took advantage of a less 
stringent regulation, besides an improvement in reimburse-
ment policies (Reim1; Table 1). However, a significant 
decrease in tramadol sales occurred at R2 and R4 (which 
mainly influence drug products included in the Annex III 
bis of Law n. 12 of 2001). Tramadol sales reached a plateau 
in the first part of 2007 (Figure 2), when the prescription of 
opioids listed in Annex III bis was extended to all patients 
(R2; Table 1).
Conclusion
Regulatory, technological, and reimbursement changes that 
occurred in Italy between 2000 and 2010 have significantly 
influenced opioid sales to community pharmacies. Among 
the factors taken into consideration, reimbursement changes 
seem to have had a strong effect on sales, confirming the 
predominant role of the Italian NHS as a service provider in 
the assurance of public healthcare. However, different drugs 
where affected to different degrees, suggesting that sales 
may also be influenced by other elements, namely, marketing 
policies or the application of superseded clinical guidelines 
and protocols.
All the factors mentioned above may affect physicians’ 
awareness about a specific medicinal product, influencing 
their prescribing choices. The introduction of oxycodone slow 
release preparations in 2004 is concurrent with a decrease 
in the use of morphine, despite the lack of any evidence of 
clinical differences or significant changes in the administra-
tion route or compliance.26 The increase in published articles 
in peer-reviewed health sciences journals between 2000 and 
2010 was ~3-times higher for oxycodone (+504%) than 
morphine (+179%).29 The higher interest for oxycodone by 
the scientific community is a consequence of its central role 
in the opioid crisis.8
In conclusion, the higher the physicians’ awareness about 
a drug, the higher the impact of regulatory, technological, and 
reimbursement changes on their prescribing practice. The 
sales of relatively new drugs (e.g., buprenorphine) seem to 
be less affected by changes in reimbursement and regulatory 
policies than that of established products (eg, codeine or fen-
tanyl). Indeed, physicians are more comfortable with “old” 
drugs, since their clinical use is supported by established 
clinical guidelines and protocols. On the contrary, new drugs 
may lack such information, inducing physicians to prescribe 
them cautiously to avoid prescribing errors.
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